Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmafile

18:45 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Pharmafile" found in our extensive news archives from over 250 global news sources.

More Information about Pharmafile on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmafile for you to read. Along with our medical data and news we also list Pharmafile Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmafile Companies for you to search.

Showing News Articles 1–25 of 1,800+ from Pharmafile

Thursday 21st February 2019

Avara Avlon falls into administration putting 270 #Bristol jobs at risk http://bit.ly/2GBOIjc  #pharma #manufacturing #uk

Avara Avlon falls into administration putting 270 #Bristol jobs at risk http://bit.ly/2GBOIjc  #pharma #manufacturing #uk

Teva settles 'pay-to-delay' case with #FTC http://bit.ly/2twOPnK  #pharma #Monopoly

Teva settles 'pay-to-delay' case with #FTC http://bit.ly/2twOPnK  #pharma #Monopoly

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death http://bit.ly/2IqgMI4  #pharma #Pfizer

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death http://bit.ly/2IqgMI4  #pharma #Pfizer

Indivior launches authorised generic version of #opioid addiction treatment #Suboxone as rival generic drugmakers enter market http://bit.ly/2V5veXi  #pharma #opioidcrisis

Indivior launches authorised generic version of #opioid addiction treatment #Suboxone as rival generic drugmakers enter market http://bit.ly/2V5veXi  #pharma #opioidcrisis

FDA halts Xencor's acute myeloid #leukaemia trial following two patient deaths http://bit.ly/2XfsQzq  #pharma #FDA #cancer #oncologypic.twitter.com/ZdqfI6ivFD

FDA halts Xencor's acute myeloid #leukaemia trial following two patient deaths http://bit.ly/2XfsQzq  #pharma #FDA #cancer #oncology

Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries http://bit.ly/2S7XTt6  #iPS細胞 #stemcells #pharmapic.twitter.com/XyEyfz3g5E

Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries http://bit.ly/2S7XTt6  #iPS細胞 #stemcells #pharma pic.twitter.com/XyEyfz3g5E

FDA halts Xencor's acute myeloid #leukaemia trial following two patient deaths http://bit.ly/2XfsQzq  #pharma #leukemiapic.twitter.com/Ec5zEmVpUd

FDA halts Xencor's acute myeloid #leukaemia trial following two patient deaths http://bit.ly/2XfsQzq  #pharma #leukemia pic.twitter.com/Ec5zEmVpUd

FDA halts Xencor's acute myeloid leukaemia trial following two patient deaths

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, its investigational CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid leukaemia and other CD123-expressing hematologic malignancies after the deaths of two patients which are considered to be “at least possibly related” to the use of the drug. The deat...

Indivior launches authorised generic version of #opioid addiction treatment #Suboxone as rival generic drugmakers enter market http://bit.ly/2V5veXi  #pharmapic.twitter.com/kTh5yngKxE

Indivior launches authorised generic version of #opioid addiction treatment #Suboxone as rival generic drugmakers enter market http://bit.ly/2V5veXi  #pharma pic.twitter.com/kTh5yngKxE

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat opioid use disorder, following a US court’s decision to open the market to generic competitors. Novartis’ Sandoz unit will begin marketing the generic opioid use treatment in the US immediately. English firm, Indivior has been battling generic drugma...

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death http://bit.ly/2IqgMI4  #pharmapic.twitter.com/bEWVsNqk3D

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death http://bit.ly/2IqgMI4  #pharma pic.twitter.com/bEWVsNqk3D

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a Rheumatology Data Safety Monitoring Board (DSMB) highlighted safety concerns in the higher of the two doses. The Board identified a higher risk of pulmonary embolism in patients taking 10mg twice daily than in patients in the tumour necrosis factor inhibitor (TNFi) control group, pr...

Teva settles 'pay-to-delay' case with #FTC http://bit.ly/2twOPnK  #pharmapic.twitter.com/YhU5pnRci3

Teva settles 'pay-to-delay' case with #FTC http://bit.ly/2twOPnK  #pharma pic.twitter.com/YhU5pnRci3

Teva settles 'pay-to-delay' case with FTC

Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving the firm’s subsidiary Cephalon. The settlement comes after Teva was made to pay the FTC $1.2 billion over so-called ‘pay-to-delay’ policies in which the firm was accused of participating in blocking the entry of generic drugs into the market by rec...

Avara Avlon falls into administration putting 270 #Bristol jobs at risk http://bit.ly/2GBOIjc  #pharmapic.twitter.com/4MV7fv4zOv

Avara Avlon falls into administration putting 270 #Bristol jobs at risk http://bit.ly/2GBOIjc  #pharma pic.twitter.com/4MV7fv4zOv

Avara Avlon falls into administration putting 270 Bristol jobs at risk

Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk. The contract development and manufacturing organisation (CDMO) is hoping to sell facilities in Avonmouth a suburb of Bristol, which it bought from AstraZeneca in 2016. read more

Wednesday 20th February 2019

We speak to Seqirus on its Flucelvax Tetra becoming the first cell-based, quadrivalent #influenza vaccine approved in Europe, and the rising threat of vaccine hesitancy http://bit.ly/2Sau4YY  #flu #pharmapic.twitter.com/CpozSbUu9C

We speak to Seqirus on its Flucelvax Tetra becoming the first cell-based, quadrivalent #influenza vaccine approved in Europe, and the rising threat of vaccine hesitancy http://bit.ly/2Sau4YY  #flu #pharma

-Janssen's esketamine recommended by #FDA panel for #depression -Feature: Can #AI solve the drug development problem? -#FMD would not apply in case of no-deal #Brexit -Gilead's CAR-T therapy #Yescarta rejected for #NHS use in Scotland Last week's TOP 10

-Janssen's esketamine recommended by #FDA panel for #depression -Feature: Can #AI solve the drug development problem? - #FMD would not apply in case of no-deal #Brexit -Gilead's CAR-T therapy

FDA approves Indian firm Alembic's generic of Teva's Diamox http://bit.ly/2VanZxv  #pharmapic.twitter.com/Ui1k6mrsgC

FDA approves Indian firm Alembic's generic of Teva's Diamox http://bit.ly/2VanZxv  #pharma pic.twitter.com/Ui1k6mrsgC

Intercept's NASH liver fibrosis drug shows promise at Phase 3 http://bit.ly/2BLBqN5  #pharmapic.twitter.com/ntLSmWayT5

Intercept's NASH liver fibrosis drug shows promise at Phase 3 http://bit.ly/2BLBqN5  #pharma pic.twitter.com/ntLSmWayT5

Intercept's NASH liver fibrosis drug shows promise at Phase 3

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH), sending the company’s shares up by 32%. The findings showed that the 25mg dose of Ocaliva met the study’s primary endpoint of fibrosis improvement (≥1 stage) with no worsening of NASH at the planned 18-month i...

FDA approves Indian firm Alembic's generic of Teva's Diamox

The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, a medication used for the treatment of various conditions including glaucoma, epilepsy, altitude sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure. The FDA granted the drug approval under the Abbreviated New Drug Application ...

Pfizer and Eli Lilly's chronic low back pain (#CLBP) treatment meets primary endpoint in Phase 3 trial http://bit.ly/2ttnHps  #BackPain @pfizer @LillyPadpic.twitter.com/3JOqJFOTh8

Pfizer and Eli Lilly's chronic low back pain ( #CLBP) treatment meets primary endpoint in Phase 3 trial http://bit.ly/2ttnHps  #BackPain @pfizer @LillyPad

Pfizer and Eli Lilly's chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial

US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 trial of patients with moderate to severe chronic low back pain (CLBP). Treatment with 10mg of tanezumab significantly improved pain at 16 weeks when compared to placebo. An estimated 33 million Americans suffer from CLBP, eight million of whom suffer from a moderate-to-severe form of the con...

Keytruda falls short at Phase 3 in advanced #LiverCancer http://bit.ly/2GPEuLk  #cancer #pharmapic.twitter.com/yGxJ3ONGpq

Keytruda falls short at Phase 3 in advanced #LiverCancer http://bit.ly/2GPEuLk  #cancer #pharma pic.twitter.com/yGxJ3ONGpq


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks